Genetic Aspects of Age-Related Macular Degeneration and Their Therapeutic Potential
Open accessThe DOI matches its Crossref record; 174 of the 181 references it cites were found in a registry or an index.
Abstract
Age-related macular degeneration (AMD) is a complex and multifactorial disease, resulting from the interaction of environmental and genetic factors. The continuous discovery of associations between genetic polymorphisms and AMD gives reason for the pivotal role attributed to the genetic component to its development. In that light, genetic tests and polygenic scores have been created to predict the risk of development and response to therapy. Still, none of them have yet been validated. Furthermore, there is no evidence from a clinical trial that the determination of the individual genetic structure can improve treatment outcomes. In this comprehensive review, we summarize the polymorphisms of the main pathogenetic ways involved in AMD development to identify which of them constitutes a potential therapeutic target. As complement overactivation plays a major role, the modulation of targeted complement proteins seems to be a promising therapeutic approach. Herein, we summarize the complement-modulating molecules now undergoing clinical trials, enlightening those in an advanced phase of trial. Gene therapy is a potential innovative one-time treatment, and its relevance is quickly evolving in the field of retinal diseases. We describe the state of the art of gene therapies now undergoing clinical trials both in the field of complement-suppressors and that of anti-VEGF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Genetic factors account for up to 70% of disease variability.”
From Genetics and Age-Related Macular Degeneration: A Practical Review for Clinicians. (2024) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Interestingly, most discovered variants are associated with all known AMD stages [1,17,24].”
From Genetics and Age-Related Macular Degeneration: A Practical Review for Clinicians. (2024) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Up to 70% of the clinical variability in AMD can be explained by genetic variants [1,17,20], meaning this disease may be amenable to personalized medical approaches.”
From Genetics and Age-Related Macular Degeneration: A Practical Review for Clinicians. (2024) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The ability to better riskstratify patients can improve outcomes by better allocating scarce resources to the patients most in need or by selecting the most effective treatment from alternatives [1,26].”
From Genetics and Age-Related Macular Degeneration: A Practical Review for Clinicians. (2024) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Other genes involving the complement cascade, lipid metabolism, extracellular matrix, and immune function have also been associated with AMD [1,17].”
From Genetics and Age-Related Macular Degeneration: A Practical Review for Clinicians. (2024) · cites this paper as [1]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wong, W. L., Su, X., Li, X., Cheung, C. M. G., Klein, R., Cheng, C.-Y., & Wong, T. Y. (2014) · The Lancet Global Health · doi:10.1016/s2214-109x(13)70145-1 · Cited by 5,331 · cited 1×
“Age-related macular degeneration (AMD) has an estimated prevalence of 8% worldwide [1].”
BackgroundKhera, A. V., Chaffin, M., Aragam, K. G., Haas, M. E., Roselli, C., Choi, S. H., Natarajan, P., Lander, E. S., Lubitz, S. A., Ellinor, P. T., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0183-z · Cited by 2,953 · cited 2×
“In the present review, we discuss the main genetic variants, focusing on molecules currently considered potential therapeutic targets that are now undergoing clinical trial [33,34].”
BackgroundComplement factor H polymorphism and age-related macular degeneration
Edwards, A. O., Ritter, R., Abel, K. J., Manning, A., Panhuysen, C., & Farrer, L. A. (2005) · Science · doi:10.1126/science.1110189 · Cited by 2,449 · cited 1×
“There is strong evidence that the rs1061170 CFH genetic variant tightly correlates to AMD [35,36] as it reduces the strength of the bond to heparan sulfate proteoglycans [58], causing lipoprotein deposition in Bruch’s membrane (BrM) and, consequently, drusen progression.”
BackgroundComplement factor H variant increases the risk of age-related macular degeneration
Haines, J. L., Hauser, M. A., Schmidt, S., Scott, W. K., Olson, L. M., Gallins, P., Spencer, K. L., Kwan, S. Y., Noureddine, M., Gilbert, J. R., et al. (2005) · Science · doi:10.1126/science.1110359 · Cited by 2,424 · cited 1×
“The mutation affects CFH in a region that binds C-reactive protein (CRP), a major marker of inflammation [59].”
BackgroundHageman, G. S., Anderson, D. H., Johnson, L. V., Hancox, L. S., Taiber, A. J., Hardisty, L. I., Hageman, J. L., Stockman, H. A., Borchardt, J. D., Gehrs, K. M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501536102 · Cited by 1,961 · cited 1×
“CFHI62V polymorphism is a protective haplotype [65].”
Fritsche, L. G., Igl, W., Bailey, J. N. C., Grassmann, F., Sengupta, S., Bragg-Gresham, J. L., Burdon, K. P., Hebbring, S. J., Wen, C., Gorski, M., et al. (2016) · Nature Genetics · doi:10.1038/ng.3448 · Cited by 1,544 · cited 5×
“The genetics of AMD is complex, involving 52 different variants in 34 genetic loci, according to the largest genome-wide association study ever conducted to date [33].”
BackgroundResultInfluentialHTRA1 Promoter Polymorphism in Wet Age-Related Macular Degeneration
DeWan, A., Liu, M., Hartman, S., Zhang, S. S.-M., Liu, D. T. L., Zhao, C., Tam, P. O. S., Chan, W. M., Lam, D. S. C., Snyder, M., et al. (2006) · Science · doi:10.1126/science.1133807 · Cited by 876 · cited 1×
“Other reports identified the regulatory region HTRA1 rs11200638 [50,51].”
BackgroundA Simplified Severity Scale for Age-Related Macular Degeneration: AREDS Report No. 18
(2005) · Archives of Ophthalmology · doi:10.1001/archopht.123.11.1570 · Cited by 807
The impact of oxidative stress and inflammation on RPE degeneration in non-neovascular AMD
Datta, S., Cano, M., Ebrahimi, K., Wang, L., & Handa, J. T. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.03.002 · Cited by 802 · cited 1×
“Moreover, the photo-oxidative stress produced by processing light for vision is a unique example of an additional source of stress [13].”
BackgroundDeveloping and evaluating polygenic risk prediction models for stratified disease prevention
Chatterjee, N., Shi, J., & García-Closas, M. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.27 · Cited by 697
Research works printed but not linked: 1
- Busbee, 2021, Phase 1 Study of Intravitreal Gene Therapy with ADVM-022 for neovascular AMD (OPTIC Trial), Investig. Ophthalmol. Vis. Sci., 62, 352
Cited by
Hernández, M. E. O., Luján, L. M. L., Burboa‐Zazueta, M. G., Castillo-Castro, T. D., Vega, E. D. L. R., Galvez-Ruiz, J. C., López, S. T., López‐Torres, M. A., & Assanga, S. B. I. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083463 · Cited by 76
“Additionally, mutations in the CFH gene are known to elevate the risk of developing AMD [12,13].”
Different Therapeutic Approaches for Dry and Wet AMD
Marchesi, N., Capierri, M., Pascale, A., & Barbieri, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252313053 · Cited by 71
“For this reason, variations in ARMS2/HTRA1 may lead, with a higher likelihood, to the development of wet AMD [32].”
Genetic Insights into Age-Related Macular Degeneration
Bhumika, Bora, N. S., & Bora, P. S. (2024) · Biomedicines · doi:10.3390/biomedicines12071479 · Cited by 35
Mimura, T., & Noma, H. (2025) · Antioxidants · doi:10.3390/antiox14101251 · Cited by 32
The impact of NF-κB on inflammatory and angiogenic processes in age-related macular degeneration
Almalki, W. H., & Almujri, S. S. (2024) · Experimental Eye Research · doi:10.1016/j.exer.2024.110111 · Cited by 22
Computational methods in glaucoma research: Current status and future outlook
Kim, M. J., Martin, C. A., Kim, J., & Jablonski, M. M. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101222 · Cited by 17
Weh, E., Goswami, M. T., Chaudhury, S., Fernando, R., Miller, N., Hager, H. M., Sheskey, S., Sharma, V., Wubben, T. J., & Besirli, C. G. (2023) · Cells · doi:10.3390/cells12162043 · Cited by 16
The role of immune modulators in age-related macular degeneration
Schloesser, L., Klose, S. M., Mauschitz, M. M., Abdullah, Z., & Finger, R. P. (2024) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2024.07.009 · Cited by 14
Genetics and Age-Related Macular Degeneration: A Practical Review for Clinicians.
Nguyen, J., Brantley, & Schwartz, S. G. (2024) · Frontiers in Bioscience-Scholar · doi:10.31083/j.fbs1601003 · Cited by 12
“The ability to better risk-stratify patients can improve outcomes by better allocating scarce resources to the patients most in need or by selecting the most effective treatment from alternatives [1,26].”
BackgroundInfluentialTherapeutic innovations for geographic atrophy: A promising horizon
Figueiredo, E. C. D. O., Bucolo, C., & Eandi, C. M. (2024) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2024.102484 · Cited by 13
“Genetic factors also significantly influence the development and progression of AMD, including GA [14,18].”
Integrative Landscape of Dry AMD Pathogenesis, Models, and Emerging Therapeutic Strategies
Bhandari, S. K., Lee, S., & Kim, H. J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010202 · Cited by 13
“Mutations in ABCA4 , typically associated with Stargardt disease, have also been implicated in specific AMD subtypes [24].”
Dietary sources of antioxidants and oxidative stress in age-related macular degeneration
Matías-Pérez, D., Varapizuela-Sánchez, C. F., Pérez‐Campos, E., González-González, S., Sánchez-Medina, M. A., & García-Montalvo, I. A. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1442548 · Cited by 8
Raimondi, R., D’Esposito, F., Sorrentino, T., Tsoutsanis, P., Rosa, F. P. D., Stradiotto, E., Barone, G., Rizzato, A., Allegrini, D., Costagliola, C., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119722 · Cited by 8
Self-citationKulbay, M., Wu, K. Y., Nirwal, G. K., Bélanger, P., & Tran, S. D. (2024) · Biomedicines · doi:10.3390/biomedicines12071579 · Cited by 15
“Other risk factors where an association was shown over the years include genetic predispositions [7], dietary intakes (e.g., a high Mediterranean diet decreases the risk of progression of AMD) [8], smoking [9,10], alcohol [11,12], and the presence of cardiovascular disease [13]. alcohol [11,12],…”
BackgroundGene therapy for retinal diseases: From genetics to treatment
Khaparde, A., Mathias, G. P., Poornachandra, B., Thirumalesh, M. B., Shetty, R., & Ghosh, A. (2024) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_2902_23 · Cited by 10
“…NCT05984927, NCT05536973, NCT05930561, NCT05748873, NCT05657301, NCT06066008, NCT05672121, NCT05197270, NCT03326336, NCT03328130, NCT03316560 [28,106,107] Retrovirus GA OAT NCT00001735 [108,109] Herpes simplex virus NA NA NA their small size, which enables cellular penetration, and their…”
Optical-Quality Assessment of a Miniaturized Intraocular Telescope
Nepita, I., Raimondi, R., Piazza, S., Diaspro, A., Vidal-Aroca, F., Surdo, S., & Romano, M. R. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12103375 · Cited by 6
“Genomic tailored therapies are an interesting possible solution, though, not clinically feasible yet [4].”
BackgroundSelf-citationČebatorienė, D., Vilkevičiūtė, A., Gedvilaitė, G., Duseikaitė, M., Bruzaite, A., Kriaučiūnienė, L., Žaliūnienė, D., & Liutkevičienė, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179750 · Cited by 5
“Improved risk stratification through clinical genetic testing can enhance patient outcomes by optimizing resource allocation and facilitating the selection of the most suitable treatment options [48,49].”
BackgroundTherapeutic potential of taurine in a pigmented rat model of age-related macular degeneration
Attia, M., Pavlovič, T., Muliawan, A., Tuya, F., Mihalatos, M., Iwanicki, M., & Kang‐Mieler, J. J. (2025) · Frontiers in Ophthalmology · doi:10.3389/fopht.2025.1701761 · Cited by 1
“Genetic models, such as RCS rats, primarily re fl ect monogenic causes of degeneration, whereas AMD arises from multifactorial genetic and environmental in fl uences (24, 25).”
Siddiqui, I., Khan, N. A., Ahmad, F., Nawaz, M., Naeem, A., Khalid, M. U., Mirza, U., Danish, H. A., & Khalid, S. S. (2024) · medRxiv · doi:10.1101/2024.09.07.24313230 · Cited by 1
“NF-κB also upregulates matrix metalloproteinases (MMPs), which degrade extracellular matrix components, leading to disruptions in Bruch's membrane and the RPE layer, and thus promoting AMD progression [113, 118].”
BackgroundAge maculodystrophia: the hypothesis of etiopathogenesis
Dmytrivna, R. O. (2023) · Advances in Ophthalmology & Visual System · doi:10.15406/aovs.2023.13.00437 · Cited by 1
Zebrafish as an experimental model for inherited retinal diseases
Takita, S., & Seko, Y. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1004858
ÖNAL, A. (2024) · Turkiye Klinikleri Journal of Ophthalmology · doi:10.5336/ophthal.2023-100690 · Cited by 1
“13 The onset and course of AMD are significantly influenced by familial variations.”
Review research designed to investigate gene function and possible impact of specific variants
Smith, M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23648-8.00010-3
Zervou, M. I., Tarlatzis, B. C., & Goulielmos, G. N. (2025) · Maturitas · doi:10.1016/j.maturitas.2025.108272
Aging as a risk factor in eye disease: Mechanisms of aging in the human body
Teren, D., & Alio, J. L. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13983-3.00002-x
Zalke, J. B., Rotake, D. R., Barve, V. P., Rout, C., Singh, S. G., & Singh, R. (2026) · Nanotechnology · doi:10.1088/1361-6528/ae6f20
Visual impairment in older women
Seay, M. D., Jensen, J., Smith, H., & Hartnett, M. E. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45863-7.00107-4
Chen, N., Liu, Y., Chen, Z., Xiang, Y., & Yu, H. (2026) · Eye and Vision · doi:10.1186/s40662-026-00502-3
“Proteins involved in metabolic and complement pathways are thought to influence AMD onset and progression, with some complement components already serving as targets for recently approved therapies [9].”
Wen, L., Li, F., Liu, Y., Zhang, K., Mao, A., Liu, L., Lv, X., Geng, L., Yu, F., Feng, L., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188103
“The vast majority of AMD-associated variants reside in non-coding regions and are presumed to influence disease susceptibility by altering transcriptional or translational abundance rather than protein-coding sequences [13,14].”
Metadata
- Authors
- Stradiotto, E., Allegrini, D., Fossati, G., Raimondi, R., Sorrentino, T., Tripepi, D., Barone, G., Inforzato, A., & Romano, M. R.
- Affiliations
- Humanitas University (IT)
- Humanitas Castelli (IT)
- Corresponding author
- Stradiotto, Elisa
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-10-31
- Volume
- 23
- Issue
- 21
- Pages
- 13280
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC9653831
- OpenAlex
- W4308124848
- Cited by
- 29
- References
- 181
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 14 · 2023: 5
- FWCI
- 1.34
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Keywords
- age-related macular degeneration, genetic polymorphism, genetic risk prediction, polygenic risk score, complement overactivation, gene therapy, anti-VEGF therapy, retinal disease, therapeutic target
- MeSH terms
- Complement System Proteins, Humans, Macular Degeneration, Polymorphism, Genetic, Angiogenesis Inhibitors, Polymorphism, Single Nucleotide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.